Ultromics announced its artificial intelligence-guided device for the diagnosis of HF with preserved ejection fraction via echocardiogram has received full marketing authorization from the FDA.
The device (EchoGo Heart Failure) was developed by Ultromics, a spin-out of the University of Oxford, in collaboration with Mayo Clinic, according to a press release issued by the company.
Read the full story in Healio.